Evidence map›Paper›PMID 27187180›Full record

ArticlePLoS pathogens2016

A Miniaturized Screen of a Schistosoma mansoni Serotonergic G Protein-Coupled Receptor Identifies Novel Classes of Parasite-Selective Inhibitors.

John D Chan, John D McCorvy, Sreemoyee Acharya, Malcolm E Johns, Timothy A Day, Bryan L Roth, Jonathan S Marchant

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Identification of annotated bioactive molecules that impair motility of the blood fluke Schistosoma mansoni.International journal for parasitology. Drugs and drug resistance · 2020
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Anthelmintics - From Discovery to Resistance III (Indian Rocks Beach, FL, 2018).International journal for parasitology. Drugs and drug resistance · 2018
    Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

John D ChanDepartment of Pharmacology, University of Minnesota, Minneapolis, Minnesota, United States of America.
John D McCorvyDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Sreemoyee AcharyaDepartment of Biomedical Sciences, Iowa State University, Ames, Iowa, United States of America.
Malcolm E JohnsDepartment of Pharmacology, University of Minnesota, Minneapolis, Minnesota, United States of America.ORCID 0000-0003-1587-2509
Timothy A DayDepartment of Biomedical Sciences, Iowa State University, Ames, Iowa, United States of America.
Bryan L RothDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Jonathan S MarchantDepartment of Pharmacology, University of Minnesota, Minneapolis, Minnesota, United States of America.
University of Minnesota · USIowa State University · USUniversity of North Carolina at Chapel Hill · US

Funding

Functional architecture of IP3-evoked local Ca2+ signalsR01GM088790 · NIGMS · UNIVERSITY OF MINNESOTA · PI MARCHANT, JONATHAN S, SLAMA, JAMES T · 2009 to 2025
$4.7M
Targeting and Trafficking of 5-HT2A Serotonin ReceptorsR01MH061887 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROTH, BRYAN L. · 2000 to 2014
$4.5M
Stem Cell Biology Training ProgramT32GM113846 · NIGMS · UNIVERSITY OF MINNESOTA · PI PERLINGEIRO, RITA C. R. · 2015 to 2019
$712k
(Re)generating new drug leads for schistosomiasisR21AI125821 · NIAID · UNIVERSITY OF MINNESOTA · PI MARCHANT, JONATHAN S · 2016 to 2018
$425k
NIAID NIH HHS R21 AI125821NIGMS NIH HHS R01 GM088790NIGMS NIH HHS T32 GM113846NIMH NIH HHS R01 MH061887
6 · The paper itself

Abstract

Schistosomiasis is a tropical parasitic disease afflicting ~200 million people worldwide and current therapy depends on a single drug (praziquantel) which exhibits several non-optimal features. These shortcomings underpin the need for next generation anthelmintics, but the process of validating physiologically relevant targets ('target selection') and pharmacologically profiling them is challenging. Remarkably, even though over a quarter of current human therapeutics target rhodopsin-like G protein coupled receptors (GPCRs), no library screen of a flatworm GPCR has yet been reported. Here, we have pharmacologically profiled a schistosome serotonergic GPCR (Sm.5HTR) implicated as a downstream modulator of PZQ efficacy, in a miniaturized screening assay compatible with high content screening. This approach employs a split luciferase based biosensor sensitive to cellular cAMP levels that resolves the proximal kinetics of GPCR modulation in intact cells. Data evidence a divergent pharmacological signature between the parasitic serotonergic receptor and the closest human GPCR homolog (Hs.5HTR7), supporting the feasibility of optimizing parasitic selective pharmacophores. New ligands, and chemical series, with potency and selectivity for Sm.5HTR over Hs.5HTR7 are identified in vitro and validated for in vivo efficacy against schistosomules and adult worms. Sm.5HTR also displayed a property resembling irreversible inactivation, a phenomenon discovered at Hs.5HTR7, which enhances the appeal of this abundantly expressed parasite GPCR as a target for anthelmintic ligand design. Overall, these data underscore the feasibility of profiling flatworm GPCRs in a high throughput screening format competent to resolve different classes of GPCR modulators. Further, these data underscore the promise of Sm.5HTR as a chemotherapeutically vulnerable node for development of next generation anthelmintics.

Indexed as

Schistosomiasis mansoniAnimalsBlotting, WesternDrug Evaluation, PreclinicalFemaleHEK293 CellsHigh-Throughput Screening AssaysHumansMiceReceptors, G-Protein-CoupledSchistosoma mansoniReceptors, G-Protein-Coupled

Identifiers

PMID27187180
PMCPMC4871480
OpenAlexW2396059683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.